Back to top

LACOG 2218 – PACIFIC BRAZIL

  /    /  LACOG 2218 – PACIFIC BRAZIL

Intensified chemo-immuno-radiotherapy with durvalumab (MEDI4736) for stage III Non-Small Cell Lung Cancers (NSCLCs): a Brazilian Single Arm Phase II study (PACIFIC BRAZIL)

Type of Study: Clinical Trial

Sponsor / Support: LACOG

Primary Objectives: The primary objective of this study is to determine the 12-month progression-free survival, defined as the proportion of patients alive and progression-free at month 12, estimated by the Kaplan Maier method.

Design: This is a prospective, non-randomized, open label, single arm, multi-institutional, phase 2 study.

Sample Size: 48 patients

Principal Investigator: William William

Countries LATAM: Brazil

Clinicaltrials.gov Identifier: NCT04230408 

The study is open to patients participation in the following research sites:

BP - A Beneficência Portuguesa de São Paulo / São Paulo / SP / Brazil

INCA - Instituto Nacional de Câncer / Rio de Janeiro / RJ / Brazil

CPO-RS - Centro de Pesquisa em Oncologia / Porto Alegre / RS / Brazil

ICESP - Instituto do Câncer do Estado de São Paulo / São Paulo / SP / Brazil